Analysts Set BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) PT at $88.00

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has been assigned a consensus rating of “Moderate Buy” from the twenty-three ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $88.00.

A number of analysts recently issued reports on BMRN shares. UBS Group reiterated a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, July 14th. Canaccord Genuity Group raised their target price on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. HC Wainwright lifted their target price on BioMarin Pharmaceutical from $50.00 to $60.00 and gave the company a “neutral” rating in a report on Friday, August 7th. The Goldman Sachs Group began coverage on BioMarin Pharmaceutical in a research report on Monday, May 11th. They set a “neutral” rating and a $69.00 price target on the stock. Finally, Wall Street Zen raised shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, August 8th.

Institutional Trading of BioMarin Pharmaceutical

Several institutional investors and hedge funds have recently bought and sold shares of the company. Elmind Capital LP purchased a new position in shares of BioMarin Pharmaceutical during the 2nd quarter valued at $2,689,340,000. ADAR1 Capital Management LLC purchased a new stake in shares of BioMarin Pharmaceutical in the second quarter worth $2,804,000. Hsbc Holdings PLC purchased a new stake in shares of BioMarin Pharmaceutical in the second quarter worth $17,640,000. EFG International AG bought a new stake in BioMarin Pharmaceutical during the second quarter valued at $1,054,000. Finally, Primecap Management Co. CA bought a new stake in BioMarin Pharmaceutical during the second quarter valued at $811,962,000. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Stock Down 1.7%

BioMarin Pharmaceutical stock opened at $67.36 on Wednesday. The firm has a 50 day simple moving average of $59.56 and a 200 day simple moving average of $57.50. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56. BioMarin Pharmaceutical has a 1-year low of $49.26 and a 1-year high of $70.98. The firm has a market capitalization of $13.04 billion, a price-to-earnings ratio of 182.05, a P/E/G ratio of 0.48 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The firm had revenue of $989.71 million for the quarter, compared to the consensus estimate of $932.03 million. During the same quarter in the prior year, the business posted $1.44 earnings per share. The business’s quarterly revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, analysts predict that BioMarin Pharmaceutical will post 4.24 earnings per share for the current year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.